Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sinovac’s Panflu Is First Chinese Avian Flu Vaccine Approved By SFDA

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Sinovac Biotech has been granted a production license for its pandemic influenza vaccine Panflu from China's State FDA, the company announced April 2. Panflu is the first vaccine approved since SFDA implemented its Special Drug Approval Procedures in 2005

You may also be interested in...

Sinovac CEO Weidong Yin On China’s Evolving Vaccine Market: An Interview With PharmAsia News

Sinovac Biotech CEO Weidong Yin recently spoke with PharmAsia News' Shanghai bureau about the Chinese vaccine market and the impact of current government policies on vaccine makers. Sinovac was established in April 2001 as a result of a joint venture between Sino Pharma, Shenzhen Kexing and Tangshan Yian. The Beijing-based company manufactured its first hepatitis A vaccine and sold its first dose in 2002. In December 2004, it was listed on the American Stock Exchange.

Spread Of H5N1 Bird Flu Virus Genetically Traced To Southern China

Researchers studying the genetic makeup of the H5N1 avian influenza virus have located the likely source of it to the Yunnan and Hunan provinces in Southern China. The strains detected in Malaysia, Thailand and Vietnam in 2002, 2003 resembled the Yunnan Province strain, they said, while the Indonesia outbreak was related to strains in Hunan during the same period. According to the scientists in a published report, poultry trade may be responsible for the strain getting to Vietnam, but a direct link from Hunan to Indonesia was not established. (Click here for more

GSK Signs Copromotion Deal With Chinese Manufacturer For Influenza Vaccine

SHANGHAI - Chinese vaccine manufacturer Sinovac Biotech will copromote its influenza vaccine Anflu with GlaxoSmithKline (China) Investment Co. under an exclusive service agreement announced Aug. 1




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts